Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2010 Oct 01;784:577-87. doi: 10.1124/mol.110.065896.
Show Gene links
Show Anatomy links
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
Desmoulin SK
,
Wang Y
,
Wu J
,
Stout M
,
Hou Z
,
Fulterer A
,
Chang MH
,
Romero MF
,
Cherian C
,
Gangjee A
,
Matherly LH
.
???displayArticle.abstract???
The proton-coupled folate transporter (PCFT) is a folate-proton symporter with an acidic pH optimum, approximating the microenvironments of solid tumors. We tested 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with one to six carbons in the bridge region for inhibition of proliferation in isogenic Chinese hamster ovary (CHO) and HeLa cells expressing PCFT or reduced folate carrier (RFC). Only analogs with three and four bridge carbons (N-{4-[3-2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)propyl]benzoyl}-L-glutamic acid (compound 2) and N-{4-[4-2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]benzoyl}*-L-glutamic acid (compound 3), respectively) were inhibitory, with 2 ≫ 3. Activity toward RFC-expressing cells was negligible. Compound 2 and pemetrexed (Pmx) competed with [(3)H]methotrexate for PCFT transport in PCFT-expressing CHO (R2/hPCFT4) cells from pH 5.5 to 7.2; inhibition increased with decreasing pH. In Xenopus laevis oocytes microinjected with PCFT cRNA, uptake of 2, like that of Pmx, was electrogenic. Cytotoxicity of 2 toward R2/hPCFT4 cells was abolished in the presence of adenosine or 5-amino-4-imidazolecarboxamide, suggesting that glycinamide ribonucleotide formyltransferase (GARFTase) in de novo purine biosynthesis was the primary target. Compound 2 decreased GTP and ATP pools by ∼50 and 75%, respectively. By an in situ GARFTase assay, 2 was ∼20-fold more inhibitory toward intracellular GARFTase than toward cell growth or colony formation. Compound 2 irreversibly inhibited clonogenicity, although this required at least 4 h of exposure. Our results document the potent antiproliferative activity of compound 2, attributable to its efficient cellular uptake by PCFT, resulting in inhibition of GARFTase and de novo purine biosynthesis. Furthermore, they establish the feasibility of selective chemotherapy drug delivery via PCFT over RFC, a process that takes advantage of a unique biological feature of solid tumors.
Assaraf,
Molecular basis of antifolate resistance.
2007, Pubmed
Assaraf,
Molecular basis of antifolate resistance.
2007,
Pubmed
Beardsley,
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
1989,
Pubmed
Bronder,
Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
2002,
Pubmed
Chattopadhyay,
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.
2007,
Pubmed
Deng,
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
2008,
Pubmed
Deng,
Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.
2009,
Pubmed
Elnakat,
Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy.
2004,
Pubmed
FARBER,
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.
1948,
Pubmed
Flintoff,
Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding.
1983,
Pubmed
Fry,
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.
1982,
Pubmed
Gangjee,
Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
2004,
Pubmed
Gibbs,
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
2005,
Pubmed
Gunshin,
Cloning and characterization of a mammalian proton-coupled metal-ion transporter.
1997,
Pubmed
,
Xenbase
Helmlinger,
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation.
1997,
Pubmed
Hilgenbrink,
Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
2005,
Pubmed
Huang,
Analysis of intracellular nucleoside triphosphate levels in normal and tumor cell lines by high-performance liquid chromatography.
2003,
Pubmed
Illei,
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
2003,
Pubmed
Laemmli,
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
1970,
Pubmed
LOWRY,
Protein measurement with the Folin phenol reagent.
1951,
Pubmed
Mackenzie,
Divalent metal-ion transporter DMT1 mediates both H+ -coupled Fe2+ transport and uncoupled fluxes.
2006,
Pubmed
,
Xenbase
Matherly,
Human reduced folate carrier: translation of basic biology to cancer etiology and therapy.
2007,
Pubmed
Matsudaira,
Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes.
1987,
Pubmed
Nakai,
Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter.
2007,
Pubmed
Qiu,
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
2006,
Pubmed
,
Xenbase
Racanelli,
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
2009,
Pubmed
Raghunand,
Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy.
1999,
Pubmed
Salazar,
The folate receptor: what does it promise in tissue-targeted therapeutics?
2007,
Pubmed
Schmid,
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
1998,
Pubmed
Smith,
Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
1993,
Pubmed
Unal,
The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1.
2009,
Pubmed
,
Xenbase
Wang,
Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
2010,
Pubmed
Wong,
Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells.
1995,
Pubmed
Zain,
Pralatrexate - from bench to bedside.
2010,
Pubmed
Zhao,
The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.
2008,
Pubmed
,
Xenbase
Zhao,
The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed.
2007,
Pubmed
Zhao,
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.
2009,
Pubmed
Zhao,
Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
2004,
Pubmed
Zhao,
A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
2004,
Pubmed
Zhao,
Resistance to antifolates.
2003,
Pubmed
